世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

NAがん免疫療法市場 - 2035年までの産業動向と予測


NA Cancer Immunotherapy Market - Industry Trends and Forecast to 2035

北米のがん免疫療法市場は、2023年の521億5,929万米ドルから2031年には1,478億2,458万米ドルに達し、2024年から2031年の予測期間中に年平均成長率14.9％で成長すると予測されている。 市場セグメンテーション ... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Data Bridge Market Research
データブリッジマーケットリサーチ 		2023年12月1日 US$3,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		251 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

北米のがん免疫療法市場は、2023年の521億5,929万米ドルから2031年には1,478億2,458万米ドルに達し、2024年から2031年の予測期間中に年平均成長率14.9％で成長すると予測されている。
市場セグメンテーション
北米がん免疫療法市場：製品タイプ別（チェックポイント阻害剤、モノクローナル抗体、ワクチン、細胞療法、免疫調節剤、がん溶解性ウイルス）、用途別（肺がん、乳がん、メラノーマ、骨髄腫、前立腺がん、卵巣がん、S.,産業動向と2031年までの予測


北米がん免疫療法市場ダイナミクスの概要

推進要因
- がん罹患率の上昇

抑制要因

- 免疫関連の有害事象の増加

機会

- 併用療法への傾向の高まり

市場プレイヤー

北米のがん免疫療法市場で事業を展開する主な市場参入企業は以下の通りである：

- メルク社
- F.ホフマン・ラ・ロシュ社
- ブリストル・マイヤーズ スクイブ社
- ヤンセンファーマ
- アストラゼネカ
- ギリアド・サイエンシズ
- イーライリリー・アンド・カンパニー
- アムジェン社
- ノバルティスAG
- GSK
- ファイザー
- インサイト


ページTOPに戻る


目次

TABLE OF CONTENTS
1 INTRODUCTION 83
1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE NORTH AMERICA CANCER IMMUNOTHERAPY MARKET 83
1.4 CURRENCY AND PRICING 85
1.5 LIMITATIONS 85
1.6 MARKETS COVERED 85
2 MARKET SEGMENTATION 89
2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 DBMR TRIPOD DATA VALIDATION MODEL 92
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 95
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 96
2.8 MARKET END USER COVERAGE GRID 97
2.9 DBMR MARKET POSITION GRID 98
2.10 VENDOR SHARE ANALYSIS 99
2.11 SECONDARY SOURCES 100
2.12 ASSUMPTIONS 100
3 EXECUTIVE SUMMARY 101
4 PREMIUM INSIGHTS 103
4.1 PESTAL ANALYSIS 104
4.2 PORTERS 5 FORCES 105
5 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET: REGULATIONS 106
6 MARKET OVERVIEW 114
6.1 DRIVERS 116
6.1.1 RISING PREVALENCE OF CANCER INCIDENCES 116
6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS 116
6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT 117
6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT 117
6.2 RESTRAINTS 118
6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS 118
6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT 118
6.3 OPPORTUNITIES 119
6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES 119
6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS 119
6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES 120
6.4 CHALLENGES 121
6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING 121
6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE 121
7 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE 122
7.1 OVERVIEW 123
7.2 CHECKPOINT INHIBITORS 126
7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1) 127
7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 127
7.3 MONOCLONAL ANTIBODIES 128
7.3.1 NAKED MONOCLONAL ANTIBODIES 129
7.3.2 CONJUGATED MONOCLONAL ANTIBODIES 129
7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES 129
7.4 VACCINES 130
7.4.1 PROPHYLACTIC VACCINES 131
7.4.2 THERAPEUTIC VACCINES 131
7.5 CELL THERAPIES 131
7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 132
7.5.2 T CELL THERAPY 132
7.6 IMMUNOMODULATORS 132
7.6.1 INTERFERONS 133
7.6.2 INTERLEUKINS 133
7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 133
7.7 ONCOLYTIC VIRUS 134
8 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY END USER 135
8.1 OVERVIEW 136
8.2 HOSPITALS 139
8.3 ONCOLOGY CLINICS 140
8.4 HOMECARE 140
8.5 OTHERS 141
9 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 142
9.1 OVERVIEW 143
9.2 DIRECT TENDERS 146
9.3 RETAIL SALES 147
9.4 PHARMACIES 147
9.4.1 HOSPITAL 148
9.4.2 RETAIL 148
9.4.3 ONLINE 148
10 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY FORM 149
10.1 OVERVIEW 150
10.2 INTRAVENOUS (IV) 153
10.3 INTRAMUSCULAR 154
10.4 ORAL 154
11 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 155
11.1 OVERVIEW 156
11.2 LUNG CANCER 159
11.2.1 CHECKPOINT INHIBITORS 160
11.2.2 MONOCLONAL ANTIBODIES 160
11.2.3 CELL THERAPIES 160
11.2.4 IMMUNOMODULATORS 160
11.3 BREAST CANCER 161
11.3.1 CHECKPOINT INHIBITORS 161
11.3.2 MONOCLONAL ANTIBODIES 161
11.3.3 CELL THERAPIES 162
11.3.4 IMMUNOMODULATORS 162
11.4 MELANOMA 162
11.4.1 CHECKPOINT INHIBITORS 163
11.4.2 MONOCLONAL ANTIBODIES 163
11.4.3 CELL THERAPIES 163
11.4.4 IMMUNOMODULATORS 163
11.4.5 ONCOLYTIC VIRUS 163
11.5 MULTIPLE MYELOMA 164
11.5.1 CHECKPOINT INHIBITORS 164
11.5.2 MONOCLONAL ANTIBODIES 164
11.5.3 CELL THERAPIES 164
11.5.4 IMMUNOMODULATORS 165
11.6 PROSTATE CANCER 165
11.6.1 CHECKPOINT INHIBITORS 165
11.6.2 MONOCLONAL ANTIBODIES 166
11.6.3 CELL THERAPIES 166
11.6.4 IMMUNOMODULATORS 166
11.6.5 VACCINES 166
11.7 OVARIAN CANCER 166
11.7.1 CHECKPOINT INHIBITORS 167
11.7.2 MONOCLONAL ANTIBODIES 167
11.7.3 CELL THERAPIES 167
11.7.4 IMMUNOMODULATORS 167
11.8 CERVICAL CANCER 168
11.8.1 CHECKPOINT INHIBITORS 168
11.8.2 MONOCLONAL ANTIBODIES 168
11.8.3 VACCINES 169
11.8.4 CELL THERAPIES 169
11.8.5 IMMUNOMODULATORS 169
11.9 STOMACH CANCER 169
11.9.1 CHECKPOINT INHIBITORS 170
11.9.2 MONOCLONAL ANTIBODIES 170
11.9.3 CELL THERAPIES 170
11.9.4 IMMUNOMODULATORS 170
11.10 COLORECTAL CANCER 170
11.10.1 CHECKPOINT INHIBITORS 171
11.10.2 MONOCLONAL ANTIBODIES 171
11.10.3 CELL THERAPIES 171
11.10.4 IMMUNOMODULATORS 171
11.11 HEAD AND NECK CANCER 172
11.11.1 CHECKPOINT INHIBITORS 172
11.11.2 MONOCLONAL ANTIBODIES 172
11.11.3 CELL THERAPIES 172
11.11.4 IMMUNOMODULATORS 173
11.12 OTHERS 173
11.12.1 CHECKPOINT INHIBITORS 173
11.12.2 MONOCLONAL ANTIBODIES 173
11.12.3 VACCINES 174
11.12.4 CELL THERAPIES 174
11.12.5 IMMUNOMODULATORS 174
12 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY REGION 175
12.1 NORTH AMERICA 177
12.1.1 U.S. 185
12.1.2 CANADA 193
12.1.3 MEXICO 201
13 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 209
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 209
14 SWOT ANALYSIS 210
15 COMPANY PROFILES 211
15.1 MERCK & CO., INC. 211
15.1.1 COMPANY SNAPSHOT 211
15.1.2 REVENUE ANALYSIS 211
15.1.3 COMPANY SHARE ANALYSIS 212
15.1.4 PRODUCT PORTFOLIO 212
15.1.5 RECENT DEVELOPMENTS 212
15.2 F. HOFFMANN-LA ROCHE LTD 213
15.2.1 COMPANY SNAPSHOT 213
15.2.2 REVENUE ANALYSIS 213
15.2.3 COMPANY SHARE ANALYSIS 214
15.2.4 PRODUCT PORTFOLIO 214
15.2.5 RECENT DEVELOPMENTS 214
15.3 BRISTOL-MYERS SQUIBB COMPANY 216
15.3.1 COMPANY SNAPSHOT 216
15.3.2 REVENUE ANALYSIS 216
15.3.3 COMPANY SHARE ANALYSIS 217
15.3.4 PRODUCT PORTFOLIO 217
15.3.5 RECENT DEVELOPMENTS 218
15.4 JANSSEN NORTH AMERICA SERVICES, LLC 219
15.4.1 COMPANY SNAPSHOT 219
15.4.2 REVENUE ANALYSIS 219
15.4.3 COMPANY SHARE ANALYSIS 220
15.4.4 PRODUCT PORTFOLIO 220
15.4.5 RECENT DEVELOPMENTS 221
15.5 ASTRAZENECA 222
15.5.1 COMPANY SNAPSHOT 222
15.5.2 REVENUE ANALYSIS 222
15.5.3 COMPANY SHARE ANALYSIS 223
15.5.4 PRODUCT PORTFOLIO 223
15.5.5 RECENT DEVELOPMENTS 224
15.6 ABBVIE INC. 225
15.6.1 COMPANY SNAPSHOT 225
15.6.2 PIPELINE PORTFOLIO 225
15.6.3 RECENT DEVELOPMENTS 225
15.7 AMGEN INC. 226
15.7.1 COMPANY SNAPSHOT 226
15.7.2 REVENUE ANALYSIS 227
15.7.3 PIPELINE PORTFOLIO 227
15.7.4 PRODUCT PORTFOLIO 228
15.7.5 RECENT DEVELOPMENTS 228
15.8 ATARA BIOTHERAPEUTICS, INC. 229
15.8.1 COMPANY SNAPSHOT 229
15.8.2 PIPELINE PORTFOLIO 229
15.8.3 RECENT DEVELOPMENTS 229
15.9 BAYER AG 230
15.9.1 COMPANY SNAPSHOT 230
15.9.2 PIPELINE PORTFOLIO 230
15.9.3 RECENT DEVELOPMENTS 230
15.10 CELLDEX THERAPEUTICS. 232
15.10.1 COMPANY SNAPSHOT 232
15.10.2 PIPELINE PORTFOLIO 232
15.10.3 RECENT DEVELOPMENTS 232
15.11 CELLECTIS 233
15.11.1 COMPANY SNAPSHOT 233
15.11.2 PIPELINE PORTFOLIO 233
15.11.3 RECENT DEVELOPMENTS 233
15.12 GILEAD SCIENCES, INC. 234
15.12.1 COMPANY SNAPSHOT 234
15.12.2 REVENUE ANALYSIS 234
15.12.3 PRODUCT PORTFOLIO 235
15.12.4 RECENT DEVELOPMENTS 235
15.13 GSK PLC. 236
15.13.1 COMPANY SNAPSHOT 236
15.13.2 REVENUE ANALYSIS 236
15.13.3 PRODUCT PORTFOLIO 237
15.13.4 RECENT DEVELOPMENTS 237
15.14 INCYTE. 238
15.14.1 COMPANY SNAPSHOT 238
15.14.2 REVENUE ANALYSIS 238
15.14.3 PRODUCT PORTFOLIO 239
15.14.4 RECENT DEVELOPMENTS 239
15.15 LILLY. 240
15.15.1 COMPANY SNAPSHOT 240
15.15.2 REVENUE ANALYSIS 241
15.15.3 PRODUCT PORTFOLIO 241
15.15.4 RECENT DEVELOPMENTS 242
15.16 NOVARTIS AG 243
15.16.1 COMPANY SNAPSHOT 243
15.16.2 REVENUE ANALYSIS 243
15.16.3 PIPELINE PORTFOLIO 244
15.16.4 PRODUCT PORTFOLIO 244
15.16.5 RECENT DEVELOPMENTS 244
15.17 PFIZER INC. 245
15.17.1 COMPANY SNAPSHOT 245
15.17.2 REVENUE ANALYSIS 245
15.17.3 PRODUCT PORTFOLIO 246
15.17.4 RECENT DEVELOPMENTS 246
16 QUESTIONNAIRE 247
17 RELATED REPORTS 251

　

ページTOPに戻る


　

Summary

The North America cancer immunotherapy market is expected to reach USD 147,824.58 million by 2031 from USD 52,159.29 million in 2023, growing at a CAGR of 14.9% during the forecast period of 2024 to 2031.
Market Segmentation
North America Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2031


Overview of North America Cancer Immunotherapy Market Dynamics

Driver
• Rising prevalence of cancer incidences

Restraint

• Increasing occurrence of immune-related adverse events

Opportunity

• Growing trend towards combination therapies

Market Players

Some of the major market players operating in the North America cancer immunotherapy market are:

• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Janssen Pharmaceutical
• AstraZeneca
• Gilead Sciences, Inc.
• Eli Lilly and Company
• Amgen Inc.
• Novartis AG
• GSK
• Pfizer Inc.
• Incyte



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 83
1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE NORTH AMERICA CANCER IMMUNOTHERAPY MARKET 83
1.4 CURRENCY AND PRICING 85
1.5 LIMITATIONS 85
1.6 MARKETS COVERED 85
2 MARKET SEGMENTATION 89
2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 DBMR TRIPOD DATA VALIDATION MODEL 92
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 95
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 96
2.8 MARKET END USER COVERAGE GRID 97
2.9 DBMR MARKET POSITION GRID 98
2.10 VENDOR SHARE ANALYSIS 99
2.11 SECONDARY SOURCES 100
2.12 ASSUMPTIONS 100
3 EXECUTIVE SUMMARY 101
4 PREMIUM INSIGHTS 103
4.1 PESTAL ANALYSIS 104
4.2 PORTERS 5 FORCES 105
5 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET: REGULATIONS 106
6 MARKET OVERVIEW 114
6.1 DRIVERS 116
6.1.1 RISING PREVALENCE OF CANCER INCIDENCES 116
6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS 116
6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT 117
6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT 117
6.2 RESTRAINTS 118
6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS 118
6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT 118
6.3 OPPORTUNITIES 119
6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES 119
6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS 119
6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES 120
6.4 CHALLENGES 121
6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING 121
6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE 121
7 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE 122
7.1 OVERVIEW 123
7.2 CHECKPOINT INHIBITORS 126
7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1) 127
7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 127
7.3 MONOCLONAL ANTIBODIES 128
7.3.1 NAKED MONOCLONAL ANTIBODIES 129
7.3.2 CONJUGATED MONOCLONAL ANTIBODIES 129
7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES 129
7.4 VACCINES 130
7.4.1 PROPHYLACTIC VACCINES 131
7.4.2 THERAPEUTIC VACCINES 131
7.5 CELL THERAPIES 131
7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 132
7.5.2 T CELL THERAPY 132
7.6 IMMUNOMODULATORS 132
7.6.1 INTERFERONS 133
7.6.2 INTERLEUKINS 133
7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 133
7.7 ONCOLYTIC VIRUS 134
8 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY END USER 135
8.1 OVERVIEW 136
8.2 HOSPITALS 139
8.3 ONCOLOGY CLINICS 140
8.4 HOMECARE 140
8.5 OTHERS 141
9 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 142
9.1 OVERVIEW 143
9.2 DIRECT TENDERS 146
9.3 RETAIL SALES 147
9.4 PHARMACIES 147
9.4.1 HOSPITAL 148
9.4.2 RETAIL 148
9.4.3 ONLINE 148
10 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY FORM 149
10.1 OVERVIEW 150
10.2 INTRAVENOUS (IV) 153
10.3 INTRAMUSCULAR 154
10.4 ORAL 154
11 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 155
11.1 OVERVIEW 156
11.2 LUNG CANCER 159
11.2.1 CHECKPOINT INHIBITORS 160
11.2.2 MONOCLONAL ANTIBODIES 160
11.2.3 CELL THERAPIES 160
11.2.4 IMMUNOMODULATORS 160
11.3 BREAST CANCER 161
11.3.1 CHECKPOINT INHIBITORS 161
11.3.2 MONOCLONAL ANTIBODIES 161
11.3.3 CELL THERAPIES 162
11.3.4 IMMUNOMODULATORS 162
11.4 MELANOMA 162
11.4.1 CHECKPOINT INHIBITORS 163
11.4.2 MONOCLONAL ANTIBODIES 163
11.4.3 CELL THERAPIES 163
11.4.4 IMMUNOMODULATORS 163
11.4.5 ONCOLYTIC VIRUS 163
11.5 MULTIPLE MYELOMA 164
11.5.1 CHECKPOINT INHIBITORS 164
11.5.2 MONOCLONAL ANTIBODIES 164
11.5.3 CELL THERAPIES 164
11.5.4 IMMUNOMODULATORS 165
11.6 PROSTATE CANCER 165
11.6.1 CHECKPOINT INHIBITORS 165
11.6.2 MONOCLONAL ANTIBODIES 166
11.6.3 CELL THERAPIES 166
11.6.4 IMMUNOMODULATORS 166
11.6.5 VACCINES 166
11.7 OVARIAN CANCER 166
11.7.1 CHECKPOINT INHIBITORS 167
11.7.2 MONOCLONAL ANTIBODIES 167
11.7.3 CELL THERAPIES 167
11.7.4 IMMUNOMODULATORS 167
11.8 CERVICAL CANCER 168
11.8.1 CHECKPOINT INHIBITORS 168
11.8.2 MONOCLONAL ANTIBODIES 168
11.8.3 VACCINES 169
11.8.4 CELL THERAPIES 169
11.8.5 IMMUNOMODULATORS 169
11.9 STOMACH CANCER 169
11.9.1 CHECKPOINT INHIBITORS 170
11.9.2 MONOCLONAL ANTIBODIES 170
11.9.3 CELL THERAPIES 170
11.9.4 IMMUNOMODULATORS 170
11.10 COLORECTAL CANCER 170
11.10.1 CHECKPOINT INHIBITORS 171
11.10.2 MONOCLONAL ANTIBODIES 171
11.10.3 CELL THERAPIES 171
11.10.4 IMMUNOMODULATORS 171
11.11 HEAD AND NECK CANCER 172
11.11.1 CHECKPOINT INHIBITORS 172
11.11.2 MONOCLONAL ANTIBODIES 172
11.11.3 CELL THERAPIES 172
11.11.4 IMMUNOMODULATORS 173
11.12 OTHERS 173
11.12.1 CHECKPOINT INHIBITORS 173
11.12.2 MONOCLONAL ANTIBODIES 173
11.12.3 VACCINES 174
11.12.4 CELL THERAPIES 174
11.12.5 IMMUNOMODULATORS 174
12 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY REGION 175
12.1 NORTH AMERICA 177
12.1.1 U.S. 185
12.1.2 CANADA 193
12.1.3 MEXICO 201
13 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 209
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 209
14 SWOT ANALYSIS 210
15 COMPANY PROFILES 211
15.1 MERCK & CO., INC. 211
15.1.1 COMPANY SNAPSHOT 211
15.1.2 REVENUE ANALYSIS 211
15.1.3 COMPANY SHARE ANALYSIS 212
15.1.4 PRODUCT PORTFOLIO 212
15.1.5 RECENT DEVELOPMENTS 212
15.2 F. HOFFMANN-LA ROCHE LTD 213
15.2.1 COMPANY SNAPSHOT 213
15.2.2 REVENUE ANALYSIS 213
15.2.3 COMPANY SHARE ANALYSIS 214
15.2.4 PRODUCT PORTFOLIO 214
15.2.5 RECENT DEVELOPMENTS 214
15.3 BRISTOL-MYERS SQUIBB COMPANY 216
15.3.1 COMPANY SNAPSHOT 216
15.3.2 REVENUE ANALYSIS 216
15.3.3 COMPANY SHARE ANALYSIS 217
15.3.4 PRODUCT PORTFOLIO 217
15.3.5 RECENT DEVELOPMENTS 218
15.4 JANSSEN NORTH AMERICA SERVICES, LLC 219
15.4.1 COMPANY SNAPSHOT 219
15.4.2 REVENUE ANALYSIS 219
15.4.3 COMPANY SHARE ANALYSIS 220
15.4.4 PRODUCT PORTFOLIO 220
15.4.5 RECENT DEVELOPMENTS 221
15.5 ASTRAZENECA 222
15.5.1 COMPANY SNAPSHOT 222
15.5.2 REVENUE ANALYSIS 222
15.5.3 COMPANY SHARE ANALYSIS 223
15.5.4 PRODUCT PORTFOLIO 223
15.5.5 RECENT DEVELOPMENTS 224
15.6 ABBVIE INC. 225
15.6.1 COMPANY SNAPSHOT 225
15.6.2 PIPELINE PORTFOLIO 225
15.6.3 RECENT DEVELOPMENTS 225
15.7 AMGEN INC. 226
15.7.1 COMPANY SNAPSHOT 226
15.7.2 REVENUE ANALYSIS 227
15.7.3 PIPELINE PORTFOLIO 227
15.7.4 PRODUCT PORTFOLIO 228
15.7.5 RECENT DEVELOPMENTS 228
15.8 ATARA BIOTHERAPEUTICS, INC. 229
15.8.1 COMPANY SNAPSHOT 229
15.8.2 PIPELINE PORTFOLIO 229
15.8.3 RECENT DEVELOPMENTS 229
15.9 BAYER AG 230
15.9.1 COMPANY SNAPSHOT 230
15.9.2 PIPELINE PORTFOLIO 230
15.9.3 RECENT DEVELOPMENTS 230
15.10 CELLDEX THERAPEUTICS. 232
15.10.1 COMPANY SNAPSHOT 232
15.10.2 PIPELINE PORTFOLIO 232
15.10.3 RECENT DEVELOPMENTS 232
15.11 CELLECTIS 233
15.11.1 COMPANY SNAPSHOT 233
15.11.2 PIPELINE PORTFOLIO 233
15.11.3 RECENT DEVELOPMENTS 233
15.12 GILEAD SCIENCES, INC. 234
15.12.1 COMPANY SNAPSHOT 234
15.12.2 REVENUE ANALYSIS 234
15.12.3 PRODUCT PORTFOLIO 235
15.12.4 RECENT DEVELOPMENTS 235
15.13 GSK PLC. 236
15.13.1 COMPANY SNAPSHOT 236
15.13.2 REVENUE ANALYSIS 236
15.13.3 PRODUCT PORTFOLIO 237
15.13.4 RECENT DEVELOPMENTS 237
15.14 INCYTE. 238
15.14.1 COMPANY SNAPSHOT 238
15.14.2 REVENUE ANALYSIS 238
15.14.3 PRODUCT PORTFOLIO 239
15.14.4 RECENT DEVELOPMENTS 239
15.15 LILLY. 240
15.15.1 COMPANY SNAPSHOT 240
15.15.2 REVENUE ANALYSIS 241
15.15.3 PRODUCT PORTFOLIO 241
15.15.4 RECENT DEVELOPMENTS 242
15.16 NOVARTIS AG 243
15.16.1 COMPANY SNAPSHOT 243
15.16.2 REVENUE ANALYSIS 243
15.16.3 PIPELINE PORTFOLIO 244
15.16.4 PRODUCT PORTFOLIO 244
15.16.5 RECENT DEVELOPMENTS 244
15.17 PFIZER INC. 245
15.17.1 COMPANY SNAPSHOT 245
15.17.2 REVENUE ANALYSIS 245
15.17.3 PRODUCT PORTFOLIO 246
15.17.4 RECENT DEVELOPMENTS 246
16 QUESTIONNAIRE 247
17 RELATED REPORTS 251

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

Data Bridge Market Research社の医薬分野での最新刊レポート

本レポートと同じKEY WORD（industry）の最新刊レポート


よくあるご質問


Data Bridge Market Research社はどのような調査会社ですか?


データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15　10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.